Since I added to a telecom/5G stock today, and I see that same stock being teased again this week, I thought I’d take this Friday opportunity to solve a teaser for you as I update you on my portfolio moves. The teaser is from Michael Robinson for his Nova-X Report ($79/year), and it sounds kind […]
I’m going to get to several updates on Real Money Portfolio stocks at the end, including those questions “What to do with Qualcomm (QCOM)?” … but first, I’m going to go through the stocks where I’ve completed my Annual Review this week. Each year I promise to re-analyze and reconsider my opinion about each stock […]
The “Trade War” is getting real, and the higher prices imposed by governments in China and the US. Tariffs are just import taxes, paid eventually by the customer, so they raise prices… which, our economist friends will tell us, suppresses demand… and since the higher price is going to a tax, not to a company, […]
Time, once again, for the Annual Review of all of the stocks I hold in the Real Money Portfolio. Many of my positions are built up over many years, and sometimes they’re stocks that don’t generate a lot of news or attention for months at a time, so I promise each January to cover every […]
The response was pretty overwhelmingly positive when I started sending out those “Trade Note” emails this week… so I’ll stick with it for a while, at least, and see how this goes. What does that mean? Same day buy/sell notes about my Real Money Portfolio will be sent to the Irregulars going forward, in hopes […]
A fantastic market last week, a terrible market this week… it’s time, once again for another episode of “Turn Off CNBC and Have Some Perspective!” I won’t go into a long screed about long-term investing here, but I thought I’d just share one of my favorite charts — I see someone post something like this […]
Happy holiday season, campers! What’s up with the Real Money Portfolio as we head into a slow Thanksgiving week? The most brutal takedown of the week was NVIDIA (NVDA), which I’m sure many of you noticed this morning — that’s a stock that hit a stop loss a while back for us (I was watching […]
There was an election on Tuesday, I hear. I voted. The counting is almost over now. Apparently the world did not end, and now we begin the campaign for the next election… everyone raise their hand who wants to vote for austerity and deficit reduction and lower spending and higher taxes and delayed Social Security […]
While we wait to see what Berkshire Hathaway’s quarter looked like, how’s the rest of the portfolio holding up? Holy Cow, Starbucks (SBUX)! Haven’t seen that stock take this big of a pop after earnings in a long time, and sentiment seems to have changed so quickly to a “this is a safe capital return […]
Is this the beginning of a 30-60% decline in the stock market? A correction to blow off a little of the excess in the valuations of growth stocks that’s almost over? Something in between? Nobody knows, and it would be silly to spend too much time guessing. We should be prepared for either — which […]
If you’re wondering whether it’s interest rates or just “worry about overvaluation or growth” that’s making the stock market go crazy this week, or whether it’s the trade war or political upheaval or something else, well, join the club. There’s some indication that traders are in fear of the “slowdown” that could be caused by […]
This past week or so has been a “holy crap” one for those who are overexposed to momentum stocks — you know the ones, they’re the stocks I keep buying in small chunks but that are very expensive and a little frightening, the ones in my portfolio that I put in that category would be […]
I feel like I’m waggling back and forth on a strange tightrope, as I’ve been doing for about a year and a half now, and I sum it up kinda like this: I’m quite nervous about the valuations of the overall market and about the massive debt load for both governments and individuals in the […]
Ligand (LGND) started us off on Monday with a huge “beat and raise” quarter — which was already at least partly in the works, since they had raised expectations earlier and made a big deal with WuXi Biologics to amend a license agreement in exchange for a $47 million up-front payment… but they did exceed […]
Hello, dear friends — I have a few portfolio updates to start with as I get you updated on a few trades that triggered since I last wrote, so adjustments to the portfolio (including a few buys and sells) will be the focus of today’s Friday File. The latest update to the Real Money Portfolio […]
I’ve only written once about the Smallcap Discoveries service, so when several readers sent in questions about its “what if you could live to 200?” pitch, I decided to dig in a little. Longevity is a frequent focus of the alternative health crowd, promising life extension to those most obviously interested in the topic (who […]
We’ve seen a long stream of earnings reports and other worthwhile bits of data on Real Money Portfolio stocks since I last wrote to you, including some that actually included some interesting news, so prepare for a lot of quick updates…. Medical Properties Trust (MPW) reported another quarter of ho-hum… pretty much met the forecasts, […]
So… what’s been happening to the Real Money Portfolio stocks this week? What else caught my eye? No transactions this week, but plenty of stuff to think about… Clean TeQ Holdings (CLQ.AX, CLQ.TO, CTEQF) announced a somewhat surprising equity raise a couple days ago. It seems inspired largely by urgency — they can’t really claim […]
The ides of February are dismal and dreary here in the wet and grey Pioneer Valley of Massachusetts, but we remain hopeful of the sunshine to come. What do I have to share with you, dear Irregulars, as we seek a little brightness to end the week? Well, I do have a few buys to […]
A few more company updates for you as we finish up the Annual Review… almost done now, though a couple stragglers remain. Medical Properties Trust (MPW) ~2% position, $9.87 cost basis, currently ~12$. I’ve held this volatile hospital REIT for more than four years now, through a couple ignored stop-loss triggers along the way when […]
So what’s going on in the world this week? Uranium caught my eye… dominant uranium miner Cameco (CCJ) is suspending production at some of their Saskatchewan operations, so the other uranium names took that as a good sign, with the juniors in the space seeing their stock prices pop (the whole sector, as represented by […]
Weekly escalations in nuclear threats, record-breaking hurricanes… what is it going to take to shake investor sentiment for more than 24 hours? The S&P 500 is ending the week only down about a third of one percent, gold is up less than 2%, this is a market that is reacting to headlines pretty quickly… but […]
I have one relatively substantial portfolio change that I telegraphed to you last week, and which has been spurred by a recent dip in one stock and good news from another. I have sold about two thirds of my position in AIG 2021 Warrants following the trigger of a stop loss in that position (because […]
Before I get into some updates on my Real Money Portfolio, I’ve got a quick look at a teaser that several of you have asked about: Keith Schaefer’s pitch for his Oil and Gas Investments Bulletin about a “perfect business model” and “everything you want as an investor.” Here’s how Keith gets our mouths watering: […]
Hello, merry Gumshoe-ers! I’m going to be on the road next week to attend two conferences, the Grant’s Interest Rate Observer conference in New York mid-week, and the MIT Sloan Conference on Friday — so I’ll be sharing some notes with you with my thoughts on what I hear at those confabs, with fingers crossed […]
I’ve got quite a lot to share as I close out my annual review process, looking at each stock I own in some detail and updating my opinion on it for you. First I’ve got the last few stocks that don’t fit into one of the sectors I’ve covered so far over the past month, […]
I’ve got a couple things to look at for you today as we close out our last working week of the year (Stock Gumshoe will be closed until after the new year, though we’ll probably have a couple quick articles for you next week). The first is a look at a Casey teaser that a […]
The market is down hard over these past couple weeks, thanks to worries about relatively steep valuations, the likelihood of an interest rate hike from the Fed next month and, much more than anything else, a full-on panic about the possibility of a Donald Trump presidency that would, one fears, bring an almost endless stream […]
Politics has everyone in a tizzy despite the dwindling uncertainty of the US presidential election, interest rates continue to be either teensy weensy or negative, and the S&P 500 is still within a rounding error of its all-time highs. Mohammed El Erian, the Allianz strategist who used to be co-brain at Pimco with Bill Gross, […]
There are a couple interesting equity-oriented presentations at the Grant’s conference that I wanted to think through a little bit more today… … the first one was from Mark Cohodes, a legendary short seller who is semi-retired now but still takes on a few targets from time to time. And gives a great, profanity-laced presentation. […]
So… what’s been happening with the stocks I follow and write about for my favorite Irregulars? We’ve had a couple weeks pass since I last checked in, thanks to my vacation and the Pan Mass Challenge, so there’s a bit to catch up on… (and thanks again to those who sponsored me, once I get […]
This percolated up to the “most asked about” teaser pitch over the weekend, and it’s easy to see why — everyone loves royalties (or as the newsletters like to call it, “getting money for free without doing any hard work”), and Sid Riggs is saying that “you can get super rich in a matter of […]
Each year I go through all of the stocks that I either own personally or have brought to the attention of the Irregulars (there’s quite a bit of overlap on those lists), and I make sure to update my thoughts and opinion on that stock in an organized and, hopefully, disciplined way — that helps […]
We were talking about Warren Buffett just yesterday, and I also recently was looking into flights to go to the annual meeting in the Spring, so everyone’s favorite avuncular billionaire was on my mind this week… and it was almost like he was talking in my ear as I was plotting this “Idea of the […]
I’ve got a teaser solution writeup for you this week too, a little stock, but I’m still working on that and I’ve got some other Friday thoughts available for you now, so we’re going to split your Friday File into two pieces today. I’ll send out part two after the market close, since it’s about […]
[Ed. Note: Dr. KSS writes about medicine and biotech stocks for the Irregulars. He has agreed to our trading restrictions, and his words and opinions are his own. You can see all of his past articles here. Enjoy!] Do you have quirky, enigmatic notions that hang with you? Douglas Hofstadter, writing in Godel, Escher and Bach: […]
I have a few updates for you this week — there was a little bit of earnings news in the Gumshoe Universe, and I did a little rebalancing in my portfolio to get cash levels up in anticipation of future buying opportunities… but first, the latest pitch for Chris Versace’s Growth & Dividend Report caught […]
All of you, dear Irregulars, know that Stock Gumshoe is not a “tip sheet,” and I don’t operate a portfolio for other people to emulate or copy, or even attempt to track the stocks we cover as if they were a portfolio of buys and sells with consistent trading advice… but I do keep a […]
I’m going to keep it brief for you today — and we’re not going to have a formal “Idea of the Month” piece for October because, well, we’re at the end of October and I haven’t recently come across a new idea that’s compelling enough for me to argue you should own it. In some […]
I’ve got a few thoughts on stocks I follow and on a portfolio move I made today to shave my risk profile a little bit, but first I thought I’d take a quick gander at the latest teaser pitch from Dr. Kent Moors. He’s pitching is Micro-Energy Trader, the small-cap portfolio he runs in an […]
This week there’s been quite a bit of news in stocks that I follow fairly closely or own or have featured in the past as “Idea of the Month” candidates for the irregulars, so I do have a bit of a teaser campaign to talk to you about (that’s the Casey bit), but I’m going […]
Just a quick note that GlaxoSmithKline released results yesterday — for those who are interested in Ligand, which I own and have written about several times over the past year, the Promacta news looked pretty good. Despite Lemelson’s short argument that Promacta is a rapidly declining and worthless drug because of better Hepatitis C treatment […]
For our Friday File fun today I’ve got a couple udpated thoughts and check-ins on some companies that I follow and have written to you about before, but I also always like to toss in a teaser solution as we go along — so first we’ll have a look at the latest pitch from Keith […]
Those who are Irregulars know that I own shares of Ligand (LGND) and suggested it last summer in the mid-$30s, and have nibbled personally on the way up. My reasons for liking Ligand are basically two: They have a royalty-driven business model that provides potential upside with low capital needs; and they have a focus […]
The following was originally published, along with this companion article, in late February. Louis Navellier is again pushing exactly the same ad teasing the same three biotech stocks, over the last three months two of them are down and one of them has popped up by about 30% (it was, of course, the one that […]
Before I get churning with this week’s Friday File, I want to take the opportunity to thank you, the Irregulars — and particularly the several new members we’ve had join up as Irregulars in the last few weeks — welcome to the club! Stock Gumshoe has always tried to balance how we do things, offering […]
I haven’t written about Benjamin Shepherd’s Global Investment Strategist in quite a long time, so when folks started asking about his pitch for “Black Rock Fuel” I thought I’d take a look for you — and it so happens that today is Friday, so we’ll be doing it Friday File-style, Irregulars only. Before I dig […]
Just noticed that I made a trade in my account and forgot to let you know … mostly because I didn’t notice that the trade happened (it was a small limit order I had in, and it triggered while I was traveling last week). So … big news? Not really, but I bought a few […]
Some more stocks from our list of speculative ideas to run through today, let’s jump right in with a look at Ligand Pharmaceuticals (LGND) and Invensense (INVN), two of the faster-growing stocks I’ve covered that are seeing rapid change, and do a quick check-in on some other tech-related stocks in our speculation list that haven’t […]
I don’t have one big thing to share with you today, or any super-sexy little teaser picks that have jumped out at me as being fun ideas to share with my favorite group of people, and I haven’t done any buying or selling this week to speak of, but there are several stocks that I […]
I’ve got a whole passel of things to comment on for you today — I want to update my thoughts on some insurance company stocks that I own and that I touted as beneficiaries of a big switch in the insurance market over the past year or so, check in on a buy and a […]
I’ve written several times that I’m very impressed with the performance and excellent business model of Ligand Pharmaceuticals (LGND), which I profiled for you back in June when it was in the low $30s and started buying a week or so later personally, but I have been waiting since then for a price dip to […]
Let me warn you up front that today’s missive might be more error-filled and brief than you’ve come to expect — thanks to a sprained thumb I’m hen-pecking my way across the keyboard and, truth be told, I’m already a bit grouchy after having slugged it out with this first sentence. But still, I can’t […]
Just FYI, I noticed that while I was on the road a limit buy order triggered for my account that I didn’t have the chance to write to you about yesterday — I bought another slug of Ligand Pharmaceuticals (LGND) at $42.50, so I’ve increased my holdings in that stock by about 50%. Now a […]
We brought you Myron Martin’s latest column for the Irregulars this morning, which included some new ideas in the junior resource stock space — that’s not where I prefer to invest most of the time, but I know a lot of you like those kinds of stocks so hopefully you find his musings to be […]
It’s been an interesting year so far — this week has helped to heal some wounds but my personal portfolio has lagged the market for much of the year, thanks largely to some substantial positions in stocks that were sensitive either to interest rate rises (like Retail Opportunity Investments Corp, ROIC, a favorite REIT) or […]
Just a quick note to let you know that the order I was talking about in the last Friday File, picking up an initial position in Ligand Pharmaceuticals (LGND), my most recent “Idea of the Month” stock, did in fact go through. So I now have a smallish position (about 2% of my stock portfolio) […]
I’ve got a couple quick personal portfolio updates to share with you today, including an add-on warrant buy, but first I thought you might enjoy a quick look at a teaser ad for one of Thomas Garrity’s picks from Cabot Small-Cap Confidential — they’re promoting this pretty actively right now as a “$20 biotech stock […]
I always have a few ideas floating around in my head and rising to fight for prominence when I’m working up to our monthly “Idea of the Month” piece for you, and this month is no different. When it comes to taking risks and making long-term speculative investments my temptation has been to look to […]
Comments
Since his buying advice the stock dropped 50%,you better short the stocks he recs ,never pay hundreds or thousends $ for...
Travis, Does LGND have to follow the royalty model? SAND turned its fortunes when it broke the mold. Perhaps LGND is go...
Travis, Does tonight's news from LGND change the assessment you made when closing position? My quick take is that expec...
Ligand Pharmaceuticals (LGND) announced a bombshell today, they're selling Promacta to Novartis and Royalty Pharma for $...
Based upon other posts, it's Ligand Pharmaceuticals (LGND). They're down more than 50%...
Thank you Travis. Yes, I noticed LGND went down 50% in the past couple months. It's either a bad sign of things to come ...
Bought into LGND on Christmas Eve, and if it wasn't for occasionally reading about your strategies including stop losses...
Travis: Kudos for selling part of the position when things looked good and for sticking to stop loss discipline for the ...
I watch stop losses for all my stocks, but don't follow them mechanically -- I take them far more seriously for momentum...
The lawsuits like that will crop up everywhere, though probably won’t mean anything — that’s just lawyers trying t...
I had a stop loss order in for Ligand as sort of a "disaster" price if the narrative really falls apart, given my assess...
Just ran into this comment when looking for some info about Ligand that I had written -- not trying to pick on the Doc, ...
Haven't written about Lichtenfeld's tease, but someone sent it to me today and it's clearly Ligand being touted as this ...
Dan: I am a little rattled because I had been intending to present Madrigal as a long idea of the month for December, an...
Dova Pharmaceuticals will be debuting by IPO shortly, and this one's interesting. It's a play on avatrombopag, a second-...
ddman92129, In my humble opinion if you simply must be in biotech, buy with the money you can afford to lose $IBB and ...
I took the "Bait" and subscribed to Riggs' "Small Cap Rocket" newsletter, but only because it came with a grantee that i...
Not 8 stocks, 8 drugs. As to whether it's LGND, there's no room for doubt given those clues: either he's recommending L...
Thanks for this. So, knowing the names of the 8 stocks themselves doesn't really matter. Now is there anyone who did j...
LGND for almost 8 points so far from 115 to 123 although it has basically just beat the IBB by a few percent....
$LGND also covered in this February article: http://www.stockgumshoe.com/2016/02/february-idea-of-the-month/ Best2You-...
Travis, I can't remember what you ended up doing with $LGND, but noticed it is now up to around 100 again. Remember a ...
Dang Travis. Have you seen Ligand $LGND lately? Doubled since Feb. They report earnings for 2Q after market closes today...
Thanks Travis, When I see a lousy looking chart and large short interest it reminds me of LGND and look what that chart...
I mean that if results are better than expected and the stock rises, there are enough short sellers that it's possible t...
...
The last time I wrote about Ligand, following that short analysis, was here: http://www.stockgumshoe.com/2014/06/points-...
Travis, What do you make of this firm's analysis of Ligand? See below. http://www.valuewalk.com/2014/06/lemelson-lig...
Dr. KSS; I wonder if you have any comment on LGND. It is a stock that Travis and I own, as likely others, which took a ...
Robert- you are correct on SVA. Dead money for months now and will likely go lower in the near future. LGND on the other...